Skip to content

Natural History Study of Patients With Centronuclear Myopathies

A Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Centronuclear Myopathies

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04977648
Acronym
NatHis-CNM
Enrollment
0
Registered
2021-07-27
Start date
2022-09-30
Completion date
2026-03-31
Last updated
2022-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Centronuclear Myopathy

Keywords

Muscular Diseases, Myopathies, Structural, Congenital, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases

Brief summary

This is a prospective, longitudinal study of the natural disease course intended to recruit approximately 60 patients with centronuclear myopathies (CNM) in Europe and the United States. The duration of the study, including the enrollment period, will be approximately 4 years. Data from the study will be used to characterize the natural disease course of CNM, to identify prognostic variables of the disease and to determine the best outcome measure(s) for the evaluation of future therapeutic approaches.

Interventions

None listed

Sponsors

Dynacure
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Months to No maximum
Healthy volunteers
No

Inclusion criteria

* 1\. Clinically symptomatic male or female subjects of all ages (newborns included) with a CNM resulting from a documented mutation in the MTM1 or DNM2 gene. * 2\. A written, signed and dated informed consent must be provided to participate in the study. For subjects \<18 years, consent of parent(s)/legal guardian(s) is required; informed assent can be obtained from the child according to local regulations. * 3\. Willing and able to comply with all protocol requirements and procedures.

Exclusion criteria

* 1\. Participation in any other interventional study. Participation in a previous study should be completed at least 4 weeks before the first study visit. * 2\. Currently undergoing or has undergone previous gene therapy or other therapy for CNM. * 3\. Current or past abuse of alcohol or recreational/narcotic drugs (with the exception of caffeine and nicotine), which in the investigator's opinion would compromise the subject's safety and/or compliance with the study procedures. * 4\. Current or relevant history of physical or psychiatric illness, that would make the subject unlikely to comply with the study procedures. (Note: Subjects in a wheelchair are not to be excluded). * 5\. Subject is mentally incapacitated, or parent(s)/legally-authorized representative are legally incapacitated or have limited legal capacity, or have lack of mental capacity to fully understand the protocol requirements and complete all study required procedures.

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in the Motor Function Measure (MFM32) for neuromuscular diseases.Baseline, Up to 36 monthsThe MFM32 assessment will be based on subject age. Scoring from 0 (cannot initiate the task) to 3 (performs the task fully).
Change from baseline in the Peak Inspiratory Pressure (PIP).Baseline, Up to 36 monthsThe PIP assessment will be based on subject age and ventilation status. Results will be expressed in cmH2O.
Change from baseline in the in Peak Expiratory Pressure (PEP).Baseline, Up to 36 monthsThe PEP assessment will be based on subject age and ventilation status. Results will be expressed in cmH2O.

Secondary

MeasureTime frameDescription
Change from baseline in the Pediatric Quality of Life inventory (PedsQL™).Baseline, Up to 36 monthsThe PedsQL™ questionnaire will be completed by the caregivers or by subjects based on subject age.
Change from baseline in the Meaningful Use of Speech Scale (MUSS).Baseline, Up to 36 monthsThe MUSS will be scored by trained site personnel based on the caregiver's or subject's reporting. Scoring from 0 (never) to 4 (always).
Change from baseline in the Assessment of Caregiver Experience with Neuromuscular Disease (ACEND).Baseline, Up to 36 monthsThe ACEND questionnaire will be completed by the caregiver for subjects in the study. Scoring from 1 (needs full time assistance) to 6 (needs no assistance).
Change from baseline in the (Pediatric) Eating Assessment Tool-10 ([Pedi]-EAT-10).Baseline, Up to 36 monthsThe (Pedi)-EAT-10 assessment will be completed by the caregiver based on subject age. Scoring from 0 (no problem) to 4 (severe problem).

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026